当前位置: 首页 > 期刊 > 《中国实用医药》 > 2009年第5期
编号:11769410
糖尿病肾病发病机制研究进展(4)
http://www.100md.com 2009年2月15日 《中国实用医药》 2009年第5期
     [16] Schrijvers BF,Flyvbjerg A,De Vriese AS.The role of vascular endothelial growth factor(VEGF) in renal pathophysiology.Kidney Int,2004,65(6):2003-2017.

    [17] 刘志红.胰岛素抵抗在糖尿病肾病发病中的作用.中国实用内科杂志,2002,22(9):519-521.

    [18] Venable ME,Zimmerman GA,McIntyre TM,et al.Platelet-activating factor:a phospholipid autacoid with diverse action.J Lipid Res,1993,34(5):691-702.

    [19] Lenz O,SJ,Stetler-Stevenson WG.Matrix metalloproteinases in renal development and disease.J Am Soc Nephrol,2000,11(3):574-581.

    [20] Nakamura N,Obayashi H,Fujii M,et al.Induction of aldose reductase in cultured human microvascular endothelial cells by advanced glycation end products.Free Radic Biol Med,2000,29(1):17-25.

    [21] Derubertis F,Rcraven PA.Activation of protein kinase C in glomerular cells in diabetes.Mechanisms and potential links to the pathogenesis of diabetic glomerulopathy.Diabetes,1994,43(1):1-8.

    [22] Heidland A,Sebekova K,Schinzel R.Advanced glycation end products and the progressive course of renal disease.Am J Kidney Dis,2001,38[4 Suppl 1]:100-106.

    [23] Wang H,Deng H,Liu W.The effects of paraoxonase-1 and oxidized low density lipoprotein on nephropathy in type-2 diabetes mellitus.Zhonghua Nei Ke Za Zhi,2002,41(3):179-182.

    [24] Korshunov SS,Skulachev VP,Starkov AA.High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria.FEBS Lett,1997,416(1):15-18., 百拇医药(苏 毅)
上一页1 2 3 4